Name | N-methyl-3-[[(4-pyridin-4-ylbenzoyl)amino]methyl]benzamide |
---|---|
Synonyms |
unii-4a0by63lar
PF-4950834 |
Description | PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC50 values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration[1]. |
---|---|
Related Catalog | |
Target |
ROCK2:8.35 nM (IC50) ROCK1:33.12 nM (IC50) PKCη:756 nM (IC50) PKA:424 nM (IC50) |
In Vitro | PF-4950834 shows inhibition against the AGC (cAMP-dependent protein kinase/protein kinase G/protein kinase C) kinase family with IC50 values of 8.35, 33.12, 102, 216, 321, 384, 411, 424, 457, 578, 736, 756 and 2900 nM for ROCK2, ROCK1, PRKG1, PKN1, SGK2, PRKG2, MSK1, PKA, PRKX, MSK2, P70S6K, PKCη and SGK1, respectively[1]. |
References |
Molecular Formula | C21H19N3O2 |
---|---|
Molecular Weight | 345.39 |
Exact Mass | 345.14800 |
PSA | 74.58000 |
LogP | 4.00390 |